At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PRME Prime Medicine, Inc.
Trading 06-23 13:46:53 EDT
3.36
-0.01
-0.45%
High3.55Low3.28Vol1.51M
Open3.29D1 Closing3.37Amplitude7.86%
Mkt Cap605.61MTradable Cap334.82MTotal Shares180.51M
T/O5.15MT/O Rate1.52%Tradable Shares99.80M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts’ Top Healthcare Picks: PROCEPT BioRobotics (PRCT), Prime Medicine, Inc. (PRME)
TIPRANKS  ·  06-23 18:30
Analysts’ Top Healthcare Picks: PROCEPT BioRobotics (PRCT), Prime Medicine, Inc. (PRME)
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Pm359 for the Treatment of Chronic Granulomatous Disease (Cgd)
THOMSON REUTERS  ·  06-22 20:00
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Pm359 for the Treatment of Chronic Granulomatous Disease (Cgd)
Prime Medicine, Inc. (PRME) Receives a Hold from Morgan Stanley
TIPRANKS  ·  06-22 00:35
Prime Medicine, Inc. (PRME) Receives a Hold from Morgan Stanley
Prime Medicine says New Zealand clears clinical trial application for Wilson disease therapy PM577a
Reuters  ·  06-18
Prime Medicine says New Zealand clears clinical trial application for Wilson disease therapy PM577a
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for Pm577a in H1069q-Mutated Wilson Disease
THOMSON REUTERS  ·  06-18
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for Pm577a in H1069q-Mutated Wilson Disease
Prime Medicine, - Phase 1/2 Trial Initiation Expected in H2 2026; Initial Data Expected in 2027
THOMSON REUTERS  ·  06-18
Prime Medicine, - Phase 1/2 Trial Initiation Expected in H2 2026; Initial Data Expected in 2027
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?
Simply Wall St.  ·  06-18
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?
Prime Medicine shareholders elect Kelly, Schenkein as Class I directors at annual meeting
Reuters  ·  06-09
Prime Medicine shareholders elect Kelly, Schenkein as Class I directors at annual meeting
Prime Medicine posts corporate deck outlining prime editing pipeline focus on Wilson disease, AATD
Reuters  ·  06-02
Prime Medicine posts corporate deck outlining prime editing pipeline focus on Wilson disease, AATD
Analysts Conflicted on These Healthcare Names: Kyverna Therapeutics, Inc. (KYTX), Immunome (IMNM) and Prime Medicine, Inc. (PRME)
TIPRANKS  ·  05-13
Analysts Conflicted on These Healthcare Names: Kyverna Therapeutics, Inc. (KYTX), Immunome (IMNM) and Prime Medicine, Inc. (PRME)
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), VistaGen Therapeutics (VTGN) and Prime Medicine, Inc. (PRME)
TIPRANKS  ·  05-09
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), VistaGen Therapeutics (VTGN) and Prime Medicine, Inc. (PRME)
Wedbush Keeps Their Buy Rating on Prime Medicine, Inc. (PRME)
TIPRANKS  ·  05-09
Wedbush Keeps Their Buy Rating on Prime Medicine, Inc. (PRME)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Whitehawk Therapeutics (WHWK), Prime Medicine, Inc. (PRME) and Argenx Se (ARGX)
TIPRANKS  ·  05-08
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Whitehawk Therapeutics (WHWK), Prime Medicine, Inc. (PRME) and Argenx Se (ARGX)
Prime Medicine Q1 EPS $(0.28) Misses $(0.25) Estimate, Sales $856.000K Miss $1.065M Estimate
Benzinga  ·  05-07
Prime Medicine Q1 EPS $(0.28) Misses $(0.25) Estimate, Sales $856.000K Miss $1.065M Estimate
Prime Medicine Q1 net loss narrows as R&D expenses fall
Reuters  ·  05-07
Prime Medicine Q1 net loss narrows as R&D expenses fall
BRIEF-Prime Medicine, Inc. Q1 EPS USD -0.28
Reuters  ·  05-07
BRIEF-Prime Medicine, Inc. Q1 EPS USD -0.28
Prime Medicine, Inc. Q1 Income From Operations USD -50.654 Million
THOMSON REUTERS  ·  05-07
Prime Medicine, Inc. Q1 Income From Operations USD -50.654 Million
Press Release: Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
Dow Jones  ·  05-07
Press Release: Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine announces annual stockholders meeting via webcast
Reuters  ·  04-23
Prime Medicine announces annual stockholders meeting via webcast
Prime Medicine CFO Svetlana Ni Makhni files initial beneficial ownership statement
Reuters  ·  04-18
Prime Medicine CFO Svetlana Ni Makhni files initial beneficial ownership statement

Introduction

Company Name.
Prime Medicine, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.
Issue price:
--